Tag Archives: New England Journal of Medicine

The NHS: Probably Still the World’s Best Health Service (BBC News / Commonwealth Fund / NEJM / NHS England / JAMA)

Posted on July 15, 2017 by Dementia and Elderly Care News

Summary The Commonwealth Fund, a US think-tank, has re-compared data from 11 countries and – to the surprise of some commentators – again ranked the UK’s NHS as the being the best national health system overall. The NHS comes first (highest rating) for … Continue reading →

Posted in BBC News, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), In the News, Integrated Care, International, Management of Condition, National, NHS, NHS England, Person-Centred Care, Quick Insights, Standards, Statistics, UK, Universal Interest | Tagged Access (Commonwealth Fund: Health Care System Performance Domain), Access to Care, Access to Services, Administrative Efficiency (Commonwealth Fund: Health Care System Performance Domain), Australia, Australia’s Single-Payer Insurance Program (Health Systems Achieve Excellence in Diverse Ways), Avoidable Premature Mortality, BBC Health News, Benchmarking, Benchmarking Tools, Canada, Cancer Survival, Cancer Survival Rates in England, Care Process (Commonwealth Fund: Health Care System Performance Domain), Care Quality, Closing the Cancer Survival Gap, Commonwealth Fund, Commonwealth Fund International Health Policy Surveys, Commonwealth Fund: Mirror Mirror International Comparisons (2017), Communication, Continuity and Feedback, Coordinated Care, Cost-Related Access Problems, Cross-Country Comparisons, Department of Health Policy and Management and Harvard Global Health Institute: Harvard T.H. Chan School of Public Health, Effective Care, Efficiency, Eleven-Country Summary Scores on Health System Performance, Engagement and Patient Preferences., Equality of Access, Equity, Equity (Commonwealth Fund Health: Care System Performance Domain), Former Health Secretary Jeremy Hunt, France, Germany, Harvard Center for Population and Development Studies: Harvard T.H. Chan School of Public Health (Cambridge MA), Health Care Outcomes, Health Care Outcomes (Commonwealth Fund: Health Care System Performance Domain), Health Care Spending as a Percentage of GDP (1980–2014), Health Care System Performance Compared to Spending, Health Care System Performance Rankings, Health System Performance Scores, International Comparisons, International Health Care Comparisons, International Perspectives, JAMA, Journal of the American Medical Association (JAMA), Kate Andrews: Institute of Economic Affairs, London School of Economics, Measurement for Quality and Cost, Mirror Mirror Measure Descriptions and Source Notes, Mortality Amenable to Health Care (2004 and 2014), National Healthcare Systems: International Comparative Rankings, Netherland’s Competing Private Insurers (Health Systems Achieve Excellence in Diverse Ways), Netherlands, New England Journal of Medicine, New Zealand, NHS Efficiency Savings, NHS Performance, NHS Quality, NHS: Rated World’s Best Health Service, Norway, Outcomes Benchmarking, Patient Engagement, Patient Safety, Patient-Centeredness, Perceived Inefficiency, Performance Comparisons, Premature Death, Preventative Care, Prevention, Preventive Care, Public Health, Quality, Quality in the NHS, Reducing Premature Mortality, Rt Hon Jeremy Hunt MP: Former Secretary of State for Health, Safe Care, Sweden, Switzerland, System Benchmarks, Timeliness of Care, UK’s National Health Service (Health Systems Achieve Excellence in Diverse Ways), United Kingdom, United States, United States Health Care System, USA | Leave a comment

National Diabetes Week 2017 (NHS England / NEJM / NHS Choices)

Posted on June 16, 2017 by Dementia and Elderly Care News

Summary National Diabetes Week falls between June 11th 2017 to June 17th 2017. To mark this event NHS England has released a short animation for the general public offering basic advice, and promoting the Diabetes Prevention Programme and Healthier You. … Continue reading →

Urine Test for Creutzfeldt-Jakob Disease (CJD)? (BBC News / MRC / JAMA Neurology / NEJM)

Posted on October 4, 2016 by Dementia and Elderly Care News

Summary It may one day be possible to use a non-invasive diagnostic urine test to discover whether or not patients have sporadic Creutzfeldt-Jakob Disease (sCJD). Full Text Link Reference A urine test for Creutzfeldt-Jakob Disease may be possible. London: Medical … Continue reading →

A Question of Height: a New Dimension in Statistical and Genetic Risk Factors? (BBC News / NHS Choices / British Journal of Psychiatry / NEJM)

Posted on April 10, 2015 by Dementia and Elderly Care News

Summary A number of studies point to the unexpected potential influence of physical height in the risks of developing various diseases (which may or may not be related). It was found last year that decreasing height is associated statistically with … Continue reading →

Posted in BBC News, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Quick Insights, Scotland, Statistics, UK, Universal Interest | Tagged Adult Height, Alzheimer Scotland Dementia Research Centre: University of Edinburgh, Atherosclerosis, Atherosclerosis (Hardening of the Arteries), Australia, BBC Health News, Behind the Headlines, British Heart Foundation, British Journal of Psychiatry, Cancer, Cancer Risk Factors, Centre for Cognitive Ageing and Cognitive Epidemiology: University of Edinburgh, Charles Perkins Centre and Exercise and Sport Sciences: University of Sydney, Coronary Artery Disease, Coronary Artery Disease (CAD), Coronary Heart Disease (CHD), Department of Epidemiology and Public Health (University College London), Division of Psychiatry: University of Edinburgh; Department of Epidemiology and Public Health: University College London, Epidemiology, Epidemiology and Statistics, ESPE: European Society for Paediatric Endocrinology, European Society for Paediatric Endocrinology Conference (2015), Genetic Risk Factors, Genetically Determined Height, Genetically Determined Height and Coronary Artery Disease, Health Survey for England, Health Survey for England (HSE), Height, Height and Cancer Risk, Height and Dementia Death, Karolinska Institute in Stockholm, Karolinska Institutet, Leducq Foundation, National Health Service (NHS) Scotland, National Institute for Health Research (NIHR), New England Journal of Medicine, Overlapping Risk Factors, Risk Factors, Risk of Coronary Artery Disease, Scottish Dementia Clinical Research Network, Scottish Health Survey, Short Stature and Dementia, Skin Cancer, Stature, Sweden, Sweden. Epidemiology, University College London, University of Cambridge, University of Edinburgh, University of Leicester, University of Sydney | Leave a comment

Malignant Melanoma: Increasing Incidence of Skin Cancer in the UK (BBC News / CRUK)

Posted on April 6, 2015 by Dementia and Elderly Care News

Summary It is estimated that 5,700 over-65s are diagnosed with malignant melanoma each year, compared to 600 in the mid-1970s. The over-65s were the first generation to “benefit” from cheaper foreign holidays and suntan salons. Risks of developing this condition … Continue reading →

Posted in BBC News, Charitable Bodies, In the News, Practical Advice, Quick Insights, Statistics, UK, Universal Interest | Tagged ABCDE Checklist, Advanced Melanoma: Improving Survival Rates, Aix-Marseille University, Arm Mole Count: Skin Cancer Risk, Awareness and Campaigns, Awareness and Understanding, Awareness Raising, Baby-Boomer Generation, BBC Health News, Bristol-Myers Squibb, British Association of Dermatologists (BAD), Cancer Research UK, Cancer Research UK (CRUK), Combination Immunotherapy, Combination Nivolumab Plus Ipilimumab, Cross Cancer Institute (Canada) Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, CRUK: Cancer Research UK, CTLA-4, Dana-Farber Cancer Institute (Boston), Department of Medical Oncology: Royal Marsden Hospital, Drug Side-Effects, Epidemiology, Epidemiology and Statistics, European Cancer Congress (2016), European Institute of Oncology, European Society for Medical Oncology, Gill Nuttall: Melanoma UK, Hôpital de La Timone, Healthy Lifestyles, Hospital General Universitario Gregorio Marañón (Madrid), Immunotherapy, Immunotherapy Drugs, Incidence of Malignant Melanoma, Ipilimumab, Istituto Nazionale Tumori Fondazione Pascale, Lifestyle, Lifestyle Advice, Lifestyle Factors, Lifestyle Risk Factors, Malignant Melanoma, Melanoma Institute Australia, Memorial Sloan Kettering Cancer Center, Merck, Netherlands Cancer Institute, New England Journal of Medicine, Nivolumab, Odense University Hospital, Package Holiday Boom, PD-1, Pembrolizumab, Peter MacCallum Cancer Centre and University of Melbourne, Prof Carole Longson: National Institute for Health and Care Excellence (NICE), Public Health, Risk Factors for Malignant Melanoma, Royal Marsden Hospital, Sammons Cancer Center (Dallas); University of Michigan, Singleton Hospital (Swansea), Skin Cancer, Skin Cancer Statistics, Smilow Cancer Hospital of the Yale-New Haven Hospital, South West Wales Cancer Institute, Sunburn, Tasman Oncology Research: Southport Gold Coast, Unhealthy Lifestyles, United Kingdom and Ireland Association of Cancer Registries, University Hospital of Siena, University of Colorado, University of Essen, University of Sydney, University of Utah, University of Zürich Hospital, Unresectable Stage III or IV Melanoma, Untreated Melanoma, Veneto Region Oncology Research Institute, Weill Cornell Medical College, Yale Cancer Center, Yale University School of Medicine | Leave a comment

Bapineuzumab Trials Results in Mild-to-Moderate Alzheimer’s Disease (New England Journal of Medicine)

Posted on January 28, 2014 by Dementia and Elderly Care News

Summary Bapineuzumab is an anti-amyloid-beta monoclonal antibody, which had shown promise for the treatment of Alzheimer’s Disease. Two double-blind, randomised, placebo-controlled, phase 3 trials have been conducted, involving 2204 patients with mild-to-moderate Alzheimer’s disease. One trial involved 1121 carriers of … Continue reading →

Posted in For Doctors (mostly), For Researchers (mostly), International, Pharmacological Treatments | Tagged Alzheimer's Disease Assessment Scale (ADAS-Cog11), Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, Apolipoprotein E, Apolipoprotein E (APOE) e4 Allele, Apolipoprotein E (APOE) Gene, Bapineuzumab 301, Bapineuzumab 302, Bapineuzumab for Mild-to-Moderate Alzheimer's Disease, Bapineuzumab Trials, Beta-Amyloid, Beta-Amyloid Plaques, Brigham and Women's Hospital: Boston, Butler Hospital, Cerebrospinal Fluid Phosphorylated Tau (Phospho-Tau) Concentrations, Cleo Roberts Center for Clinical Research, Clinical Trials Number NCT00574132, Clinical Trials Number NCT00575055, Columbia University, Disability Assessment for Dementia-DAD, EudraCT Number 2009-012748-17, Institute of Neurology: University College London, Janssen Alzheimer Immunotherapy and Pfizer, Janssen Alzheimer Immunotherapy Research and Development, New England Journal of Medicine, New York University Langone Medical Center, Pfizer, Pittsburgh Compound B (PIB-PET), Sahlgrenska University Hospital, Sun Health Research Institute, Sweden, University College London, University of California, University of Göteborg, University of Pittsburgh, University of Rochester School of Medicine and Dentistry, Veterans Affairs Medical Center | Leave a comment

Solanezumab Trials Results for Mild-to-Moderate Alzheimer’s Disease (New England Journal of Medicine)

Posted on January 28, 2014 by Dementia and Elderly Care News

Summary Solanezumab is a monoclonal antibody which binds soluble amyloid preferentially and had shown some promise of promoting better clearance of amyloid-beta from the brain in pre-clinical studies. Two placebo controlled trials (EXPEDITION 1 and EXPEDITION 2) of 1012 and … Continue reading →

Posted in For Doctors (mostly), For Researchers (mostly), International, Pharmacological Treatments | Tagged Alzheimer's Disease and Memory Disorders Center: Baylor College of Medicine (Houston), Alzheimer's Disease Assessment Scale (ADAS-Cog11), Alzheimer's Disease Cooperative Study Steering Committee, Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL), Alzheimer's Disease Cooperative Study: University of California at San Diego, Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, Baylor College of Medicine, Beta-Amyloid, Beta-Amyloid Plaques, Center for Human Experimental Therapeutics: University of Rochester Medical Center, Centre Hospitalier Universitaire Toulouse, Clinical Trials Number: NCT00904683, Clinical Trials Number: NCT00905372, Department of Neuropathology: University of Tokyo, Eli Lilly, Gerontopole: Unité Mixte de Recherche, Gliosis, Indiana Alzheimer Disease Center: Indiana University, Indiana University, β-amyloid, Neurofibrillary Tangles, Neuronal Loss, New England Journal of Medicine, Solanezumab for Mild-to-Moderate Alzheimer’s Disease, Solanezumab Study Group, Solanezumab Trials, Solanezumab: Humanised Monoclonal Antibody, University of California at San Diego, University of Pennsylvania, University of Rochester Medical Center | Leave a comment

Tag Archives: New England Journal of Medicine

National Diabetes Week 2017 (NHS England / NEJM / NHS Choices)

A Question of Height: a New Dimension in Statistical and Genetic Risk Factors? (BBC News / NHS Choices / British Journal of Psychiatry / NEJM)

Malignant Melanoma: Increasing Incidence of Skin Cancer in the UK (BBC News / CRUK)

Bapineuzumab Trials Results in Mild-to-Moderate Alzheimer’s Disease (New England Journal of Medicine)

Solanezumab Trials Results for Mild-to-Moderate Alzheimer’s Disease (New England Journal of Medicine)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites